{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:53Z","timestamp":1782992213756,"version":"3.54.5"},"reference-count":80,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014936","name":"BioDelivery Sciences International, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014936","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MedLogix Communications"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pain Manag."],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.2217\/pmt-2020-0013","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T11:52:13Z","timestamp":1589284333000},"page":"213-223","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Buprenorphine Buccal Film for Chronic Pain Management"],"prefix":"10.1080","volume":"10","author":[{"given":"Martin","family":"Hale","sequence":"first","affiliation":[{"name":"Gold Coast Research, LLC, 499 NW 70th Ave #200, Plantation, FL 33317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gimbel","sequence":"additional","affiliation":[{"name":"Arizona Research Center, 15601 N 28th Ave #100, Phoenix, AZ 85053, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rauck","sequence":"additional","affiliation":[{"name":"Carolinas Pain Institute, 145 Kimel Park Dr #330, Winston-Salem, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6736a2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0953-z"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2775"},{"key":"e_1_3_3_6_1","unstructured":"National Institute on Drug Abuse\n. Prescription opioids (2019). https:\/\/www.drugabuse.gov\/publications\/drugfacts\/prescription-opioids"},{"key":"e_1_3_3_7_1","unstructured":"Hedegaard H Mini\u00f1oAM WarnerM. Drug overdose deaths in the United States 1999\u20132017. NCHS Data Brief No. 329 November 2018. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db329.htm"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1003-8"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-00143-6"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S85951"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2843-9"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s12160400"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(99)00074-4"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003145"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2007.00824.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2012.05.002"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100670200031"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2010.05.035"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.06.015"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.04.018"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/216725"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.11.92"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.873714"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.001"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000144"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.06.012"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.08.001"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181673b65"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.767331"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000068"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2741\/2147"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.11.71"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.667073"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0151-y"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S132595"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90019-1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.11.91"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.008"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2011.06.003"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.04.006"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.11.93"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.09.016"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2014.992715"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.01.013"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12281"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000670"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S120170"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1128307"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01189.x"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.03.024"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw097"},{"key":"e_1_3_3_52_1","unstructured":"Belbuca [package insert]\n. BioDelivery Sciences International Inc.Raleigh NC USA (2019)."},{"key":"e_1_3_3_53_1","unstructured":"Butrans [package insert]\n. Purdue Pharma L.P. Stamford CT USA (2019)."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S140320"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.06.014"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S87952"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2002.tb00235.x"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.04.006"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.11.91"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx235"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S90780"},{"key":"e_1_3_3_62_1","unstructured":"goodRX\n. Belbuca (2020). https:\/\/www.goodrx.com\/belbuca?dosage=75mcg&form=film&label_override=Belbuca&quantity=60"},{"key":"e_1_3_3_63_1","unstructured":"goodRX\n. Butrans buprenorphine (2020). https:\/\/www.goodrx.com\/butrans?dosage=4-patches-of-5mcg&form=carton&label_override=Butrans&quantity=1"},{"key":"e_1_3_3_64_1","article-title":"Limited access to on-label formulations of buprenorphine for chronic pain as compared with conventional opioids","author":"Fishman MA","year":"2019","unstructured":"Fishman MA , SchererA , TopferJ , KimPSH. Limited access to on-label formulations of buprenorphine for chronic pain as compared with conventional opioids. Pain Med.(2019) (Epub ahead of print).","journal-title":"Pain Med."},{"issue":"3","key":"e_1_3_3_65_1","first-page":"5","article-title":"Drugs induced nausea and vomiting: an overview","volume":"11","author":"Aung T","year":"2016","unstructured":"Aung T , SooS. Drugs induced nausea and vomiting: an overview. J. Pharm. Biol. Sci.11(3), 5\u20139 (2016).","journal-title":"J. Pharm. Biol. Sci."},{"issue":"5","key":"e_1_3_3_66_1","first-page":"899","article-title":"Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine","volume":"17","author":"Webster L","year":"2016","unstructured":"Webster L , GruenerD , KirbyT , XiangQ , TzanisE , FinnA. Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine. Pain Med.17(5), 899\u2013907 (2016).","journal-title":"Pain Med."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12196"},{"key":"e_1_3_3_68_1","unstructured":"Opana ER [package insert]\n. Endo Pharmaceuticals Inc. PA USA (2019)."},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.484723"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12377"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S231948"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_208_16"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen094"},{"key":"e_1_3_3_74_1","unstructured":"Substance Abuse and Mental Health Services Administration\n. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068 NSDUH Series H-54). Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration Rockville MD (2019). https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHNationalFindingsReport2018\/NSDUHNationalFindingsReport2018.pdf"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz356"},{"issue":"1","key":"e_1_3_3_76_1","first-page":"361","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockade effects","volume":"274","author":"Walsh SL","year":"1995","unstructured":"Walsh SL , PrestonKL , BigelowGE , StitzerML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther.274(1), 361\u2013372 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aei145"},{"key":"e_1_3_3_78_1","unstructured":"US Department of Health and Human Services\n. Report on pain management best practices: updates gaps inconsistencies and recommendations (2019). https:\/\/www.hhs.gov\/ash\/advisory-committees\/pain\/reports\/index.html"},{"key":"e_1_3_3_79_1","unstructured":"Drug Enforcement Administration Diversion Control Division\n. Schedules of controlled substances: rescheduling of buprenorphine from Schedule V to Schedule III. (2002). https:\/\/www.deadiversion.usdoj.gov\/fed_regs\/rules\/2002\/fr1007.htm"},{"key":"e_1_3_3_80_1","unstructured":"United States National Library of Medicine\n. Single dose crossover study to compare the respiratory drive after administration of belbuca oxycodone and placebo. (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03996694?term=NCT03996694&rank=1"},{"key":"e_1_3_3_81_1","volume-title":"StatPearls","author":"Preuss CV","year":"2019","unstructured":"Preuss CV , KalavaA , KingKC. Prescription of controlled substances: benefits and risks. In: StatPearls. StatPearls Publishing, Treasure Island FL, USA (2019). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537318\/"},{"key":"e_1_3_3_82_1","unstructured":"United States Department of Health and Human Services\n. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. (2019). https:\/\/www.hhs.gov\/opioids\/sites\/default\/files\/2019-10\/Dosage_Reduction_Discontinuation.pdf"}],"container-title":["Pain Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pmt-2020-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:17:13Z","timestamp":1715941033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pmt-2020-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.2217\/pmt-2020-0013"],"URL":"https:\/\/doi.org\/10.2217\/pmt-2020-0013","relation":{},"ISSN":["1758-1869","1758-1877"],"issn-type":[{"value":"1758-1869","type":"print"},{"value":"1758-1877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}